Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
Abstract Introduction To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.640 |
| _version_ | 1811229951516475392 |
|---|---|
| author | Parham Sendi Marc Thierstein Nadja Widmer Flora Babongo Bosombo Annina Elisabeth Büchi Dominik Güntensperger Manuel Raphael Blum Rossella Baldan Caroline Tinguely Brigitta Gahl Dik Heg Elitza S. Theel Elie Berbari Andrea Endimiani Peter Gowland Christoph Niederhauser for the PoliCOV‐19 study |
| author_facet | Parham Sendi Marc Thierstein Nadja Widmer Flora Babongo Bosombo Annina Elisabeth Büchi Dominik Güntensperger Manuel Raphael Blum Rossella Baldan Caroline Tinguely Brigitta Gahl Dik Heg Elitza S. Theel Elie Berbari Andrea Endimiani Peter Gowland Christoph Niederhauser for the PoliCOV‐19 study |
| author_sort | Parham Sendi |
| collection | DOAJ |
| description | Abstract Introduction To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurveillance results after a vaccination campaign. Methods The cohort consists of 1022 study participants. The 3‐ and 6‐month follow‐up visits were performed in April/May and September 2021. Data on infection and vaccination rates were obtained via measuring antibodies to the nucleocapsid protein and spike protein and online questionnaires. Results The mean age of the population was 41 (SD 8.8) years, 72% were male and 76% had no comorbidity. Seroconversion was identified in 1.05% of the study population at the 3‐month visit and in 0.73% at the 6‐month visit, resulting in an infection rate of 1.8% over a time period of 6 months. In comparison, the infection rate in the general population over the same time period was higher (3.18%, p = .018). At the 6‐month visit, 77.8% of participants reported being vaccinated once and 70.5% twice; 81% had an anti‐S antibody titer of >250 U/ml and 87.1% of ≥2 U/ml. No significant association between infection and job role within the department, working region, or years of experience in the job was found. Anti‐spike antibody titers of vaccinated study participants showed a calculated decreasing trend 150–200 days after the second vaccine dose. Conclusion These data confirm the value of the vaccination campaign in an exposed group other than healthcare professionals. |
| first_indexed | 2024-04-12T10:21:56Z |
| format | Article |
| id | doaj.art-cb6c648426ec4084bc271018c3a8ac76 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-04-12T10:21:56Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-cb6c648426ec4084bc271018c3a8ac762022-12-22T03:37:04ZengWileyImmunity, Inflammation and Disease2050-45272022-07-01107n/an/a10.1002/iid3.640Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohortParham Sendi0Marc Thierstein1Nadja Widmer2Flora Babongo Bosombo3Annina Elisabeth Büchi4Dominik Güntensperger5Manuel Raphael Blum6Rossella Baldan7Caroline Tinguely8Brigitta Gahl9Dik Heg10Elitza S. Theel11Elie Berbari12Andrea Endimiani13Peter Gowland14Christoph Niederhauser15for the PoliCOV‐19 studyInstitute for Infectious Diseases, University of Bern Bern SwitzerlandDivision Operations Cantonal Police Bern Bern SwitzerlandInterregional Blood Transfusion Swiss Red Cross Bern SwitzerlandCTU Bern, University of Bern Bern SwitzerlandDepartment of Emergency Medicine Inselspital, Bern University Hospital, University of Bern Bern SwitzerlandCTU Bern, University of Bern Bern SwitzerlandDepartment of General Internal Medicine Inselspital, Bern University Hospital, University of Bern Bern SwitzerlandInstitute for Infectious Diseases, University of Bern Bern SwitzerlandInterregional Blood Transfusion Swiss Red Cross Bern SwitzerlandCTU Bern, University of Bern Bern SwitzerlandCTU Bern, University of Bern Bern SwitzerlandDivision of Clinical Microbiology Mayo Clinic Rochester Minnesota USADivision of Infectious Diseases Mayo Clinic Rochester Minnesota USAInstitute for Infectious Diseases, University of Bern Bern SwitzerlandInterregional Blood Transfusion Swiss Red Cross Bern SwitzerlandInstitute for Infectious Diseases, University of Bern Bern SwitzerlandAbstract Introduction To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurveillance results after a vaccination campaign. Methods The cohort consists of 1022 study participants. The 3‐ and 6‐month follow‐up visits were performed in April/May and September 2021. Data on infection and vaccination rates were obtained via measuring antibodies to the nucleocapsid protein and spike protein and online questionnaires. Results The mean age of the population was 41 (SD 8.8) years, 72% were male and 76% had no comorbidity. Seroconversion was identified in 1.05% of the study population at the 3‐month visit and in 0.73% at the 6‐month visit, resulting in an infection rate of 1.8% over a time period of 6 months. In comparison, the infection rate in the general population over the same time period was higher (3.18%, p = .018). At the 6‐month visit, 77.8% of participants reported being vaccinated once and 70.5% twice; 81% had an anti‐S antibody titer of >250 U/ml and 87.1% of ≥2 U/ml. No significant association between infection and job role within the department, working region, or years of experience in the job was found. Anti‐spike antibody titers of vaccinated study participants showed a calculated decreasing trend 150–200 days after the second vaccine dose. Conclusion These data confirm the value of the vaccination campaign in an exposed group other than healthcare professionals.https://doi.org/10.1002/iid3.640anti‐NCP‐antibodiesanti‐S‐antibodiesCOVID‐19 seroprevalenceSARS‐CoV‐2 |
| spellingShingle | Parham Sendi Marc Thierstein Nadja Widmer Flora Babongo Bosombo Annina Elisabeth Büchi Dominik Güntensperger Manuel Raphael Blum Rossella Baldan Caroline Tinguely Brigitta Gahl Dik Heg Elitza S. Theel Elie Berbari Andrea Endimiani Peter Gowland Christoph Niederhauser for the PoliCOV‐19 study Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort Immunity, Inflammation and Disease anti‐NCP‐antibodies anti‐S‐antibodies COVID‐19 seroprevalence SARS‐CoV‐2 |
| title | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
| title_full | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
| title_fullStr | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
| title_full_unstemmed | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
| title_short | Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort |
| title_sort | serosurveillance after a covid 19 vaccine campaign in a swiss police cohort |
| topic | anti‐NCP‐antibodies anti‐S‐antibodies COVID‐19 seroprevalence SARS‐CoV‐2 |
| url | https://doi.org/10.1002/iid3.640 |
| work_keys_str_mv | AT parhamsendi serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT marcthierstein serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT nadjawidmer serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT florababongobosombo serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT anninaelisabethbuchi serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT dominikguntensperger serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT manuelraphaelblum serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT rossellabaldan serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT carolinetinguely serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT brigittagahl serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT dikheg serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT elitzastheel serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT elieberbari serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT andreaendimiani serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT petergowland serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT christophniederhauser serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort AT forthepolicov19study serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort |